Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer InstituteSecondVersamune®platform candidate ...

PDS Biotechnology (PDSB) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application filed in ...

“MUC1 is over-expressed in multiple solid tumors including colon, pancreatic, ovarian, breast, and NSCLC, and is associated with drug resistance and poor patient outcomes. This results in an ...

"MUC1 is over-expressed in multiple solid tumors including colon, pancreatic, ovarian, breast, and NSCLC, and is associated with drug resistance and poor patient outcomes. This results in an unmet ...

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...

Expression of the transmembrane mucin MUC1 is upregulated in response to chronic inflammation. Aberrant overexpression of transmembrane mucins is associated with diverse human carcinomas and ...

PDS Biotechnology (NASDAQ:PDSB) said on Thursday it received U.S. FDA clearance for its Investigational New Drug application ...

4 Fig 1. Bispecific ADC Examples: AZD9592 recognizes EGFR and MET; M1231 recognizes EGFR and MUC1; BL-B01D1 recognizes EGFR and HER3 5. Image Credit: Sino Biological Inc. An example of this is the ...